http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-202190447-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-322 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C229-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| filingDate | 2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-202190447-A1 |
| titleOfInvention | A NEW MAGNESIUM SERInate COMPOUND AND ITS APPLICATIONS |
| abstract | The invention relates to a novel magnesium serinate compound and its use, and more particularly to a novel magnesium serinate compound in which a magnesium atom is chelated with L-serine, and to its pharmaceutical use against diseases of the central nervous system or the like. It was confirmed that the new composition of magnesium serinate obtained by the production method of the present invention, consisting of approximately 10% magnesium and approximately 90% serine, as determined by instrumental analysis, when solubilized at a concentration of approximately 500 mg/ml in water at room temperature at a value of pH 6.0 to 10.0, remained as an aqueous solution without precipitation, and no precipitation was observed when solubilized at a concentration of approximately 500 mg/ml in phosphate buffered saline (PBS) at room temperature. Thus, the new composition of magnesium serinate has properties suitable for administration orally or by injection into the human body. In addition, the compound activates mitochondrial function and proliferation of nerve cells by increasing the level of mitochondrial oxygen consumption and exhibits a protective effect on nerve cells by inhibiting nerve cell death due to possible damage to the mitochondrial membrane and/or endoplasmic reticulum stress caused by oxidative stress, and demonstrates improved permeability of the blood-brain barrier. Therefore, the compound has an excellent effect in preventing, treating and alleviating diseases of the central nervous system such as cognitive impairment, mental retardation, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorders, Down syndrome, Rett syndrome, fragile X syndrome. -chromosomes, Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, and thus the present invention is very useful for the pharmaceutical industry, etc. |
| priorityDate | 2018-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.